Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by Sporos Bioventures, LLC.  The funds will advance Stellanova’s lead antibody asset to first-in-human clinical trials for oncology, establish its discovery platform, and build its team.

Stellanova News

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing
Stellanova News

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable. Houston, …

Read More →

We use cookies to personalize your experience. By using our website you agree to our terms and conditions and privacy policy.